Newsletter
Zydus Lifesciences is buying US-based drugmaker Assertio Holdings in an all-cash deal worth around ₹1,600 crore ($166 million).
What the company does: the company focuses on supportive cancer care. Its key product, Rolvedon, helps cancer patients undergoing chemotherapy reduce the risk of serious infections by boosting immunity.
Why this matters: the acquisition gives Zydus instant access to an established US network for speciality and cancer medicines, including distribution channels and relationships with oncology experts.
This allows the company to expand faster in the high-value US healthcare market instead of building the business from scratch.
The bigger picture: the deal is part of Zydus’ long-term push to move beyond low-margin generic medicines and grow its speciality and oncology business in the US. It also positions the company to benefit from the fast-growing global oncology market, which is expected to expand from about $280 billion in 2026 to nearly $750 billion by 2035.
More broadly, the move reflects a larger shift among Indian pharma companies toward speciality drugs, biologics, and complex therapies as pricing pressure rises in the generic medicines business.
Towards Healthcare
